Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Office of Pharmaceutical Science

Executive Summary

Office of Testing & Research Director Ajaz Hussain, PhD, appointed Office of Pharmaceutical Science acting deputy director, effective April 9. Hussain will fill the position left vacant by Eric Sheinin's departure to the U.S. Pharmacopeia (1"The Pink Sheet" Jan. 8, p. 23). During Hussain's detail, Laboratory for Clinical Pharmacology Director Jerry Collins, PhD, will serve as the acting director of OTR

You may also be interested in...



FDA Pharmaceutical Science's Sheinin To Join USP After 30 Years At Agency

Office of Pharmaceutical Science Deputy Director Eric Sheinin, PhD, will oversee the USP expert committees responsible for the General Chapters section of The U.S. Pharmacopeia in his new position as USP VP-general policy & requirements.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS037632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel